The development of a new bioartificial liver and its application in 12 acute liver failure patients

Table 1 Clinical data of the patients

Patient No.	Sex	Age	Hepatitis B infection	Regimen of treatment	Number of treatment	Result
1	M	13	+	HBAL (CC)	1	Improved
2	M	38	+	1. HBAL (BAC)	1	Improved
				2. BAL	1
3	F	34	+	HBAL (BAC)	1	Improved
4	M	55	+	HBAL (BAC)	1	Death
5	M	52	+	HBAL (BAC)	1	Improved
6	M	46	+	HBAL (BAC)	1	Improved
7	M	58	+	HBAL (BAC)	1	Improved
8	M	33	+	PE and BAL	1	Improved
9	F	50	+	PE and BAL	2	Death
10	F	52	+	HF and BAL	1	Death
11	M	40	+	HF and BAL	1	Improved
12	M	30	+	BAC and BAL	1	Improved

M: Male, F: Female, +: Positive, HBAL: Hybrid bioartificial liver, BAL: Bioartificial liver, (CC): With charcoal column, (BAC): With bilirubin absorption column, PE and BAL: Plasma exchange and 24 hours later BAL only, HF and BAL: Hemofiltration and 24 hours later BAL only, BAC and BAL: Bilirubin absorption and 24 hours later BAL only.

Table 2 Change of some biochemical index after the HBAL treatment

	Time	ALT (U/L)	GOT (U/L)	TBI (µmol/L)	DBI (µmol/L)	TP (g/L)	ALB (g/L)	PT (s)
	Admission	77.5	58.8	341.8	265.4	60.1	32.8	68.8
	2 hours later	58.7	52.5	343.0	255.2	52.4	31.9	32.2
HBAL	4 hours later	66.3	69.5	345.7	280.4	52.9	31.4	40.9
(BA)	6 hours later	68.7	79.9	260.8	291.6	54.5	31.4	26.7
	2 days later	80.6	68.0	423.2	336.0	70.4	37.1	20.2
	Before HBAL	421.2	371.9	375.4	109.0	44.6	27.4	21.9
	2 hours later	427.9	412.0	389.0	102.1	42.7	26.5	28.5
HBAL	4 hours later	431.8	411.4	373.9	99.5	43.0	26.7	28.7
	6 hours later	371.0	218.0	339.8	122.1	45.6	28.8	17.4
	2 days later	301.2	159.6	444.6	125.7	43.6	26.5	28.7

HBAL: Hybrid bioartificial liver; BA: Bilirubin absorption.